Tempus AI, Inc. 8K

Tempus AI, Inc. reported strong Q1 2026 revenue growth and improved adjusted profitability, raised its 2026 revenue and Adjusted EBITDA guidance, and announced several new strategic collaborations and upcoming Investor Day plans, while continuing to operate at a GAAP net loss.

Tempus AI, Inc. reported its unaudited financial results for the quarter ended March 31, 2026, highlighting 36.1% year-over-year revenue growth to $348.1 million driven by strong performance in Diagnostics (up 34.7% to $261.1 million) and Data and Applications (up 40.5% to $87.0 million), along with a substantial increase in MRD test volume and improved non-GAAP profitability metrics, while still recording a GAAP net loss of $125.9 million. The company ended the quarter with $643.8 million in cash and marketable securities, posted adjusted EBITDA of negative $2.8 million (a significant improvement from the prior year period), and raised its full-year 2026 revenue guidance to a range of $1.59–$1.60 billion with an expected full-year 2026 Adjusted EBITDA of approximately $65 million. Tempus also announced multiple new and expanded strategic collaborations (including Merck, Gilead, Northwestern Medicine, NYU Langone Health, and Blood Cancer United), published clinical and AI-focused study results, and detailed plans for an inaugural Investor Day while providing reconciliations of GAAP to non-GAAP financial metrics and reiterating standard forward-looking statement disclosures.

Filing Facts

CIK

1717115

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-206317

Alert Tier

7